Index 45. Jahrgang, 2006 Inhalte Keywords
Transkript
Index 45. Jahrgang, 2006 Inhalte Keywords
Herausgeber: Deutsche Gesellschaft für Nuklearmedizin (DGN) Österreichische Gesellschaft für Nuklearmedizin (ÖGN) Schweizerische Gesellschaft für Nuklearmedizin (SGNM/SSNM) Schattauer GmbH Schriftleiter: O. Schober (verantwortlich) Index 45. Jahrgang, 2006 Inhalte Keywords Sektionseditoren: P. Bartenstein (Kasuistik, Leserbriefe) F. Bengel (Kardiologie, Pulmologie) H. A. Bockisch (Onkologie, Systemerkrankungen) T. Kuwert (Neuromedizin, Nephrologie, Gastroenterologie) A. A. Lammertsma (Medizin. Physik, Strahlenschutz) Chr. Eilles (Endokrinologie, Gesundheitsökonomie) P. A. Schubiger (Radiochemie, Radiopharmazie) I. Virgolini (Molecular Therapy) I. Carrio (EJNM/EANM) H. Schelbert (SNM/JNM) E. Fleck (Kardiologie) G. Gademann (Radioonkologie) H.-J. Heinze (Neurologie) H. Jürgens (Onkologie) E. Rummeny (Radiologie) Schlüsselworte Autoren Honorar-Editoren: U. Büll H. Schicha http://www.nuklearmedizin-online.de Inhalt – Nuklearmedizin 2006; 45 (1-6) Abstracts 44. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin .......................2: A4–A126 7th Annual Congress Swiss Society of Nuclear Medicine...................................3: A134–A146 6. Nationales Symposium der Österreichischen Gesellschaft für Nuklearmedizin ...................................................................................................6: A148–A161 Editorial Chr. Reiners Iodblockade der Schilddrüse bei kerntechnischen Unfällen .................................................97 Originalarbeiten – Original Articles A. Stamm-Meyer, D. Noßke, P. Schnell-Inderst, M. Hacker, K. Hahn and G. Brix Diagnostic nuclear medicine procedures in Germany between 1996 and 2002 Nuklearmedizinische Untersuchungen in Deutschland zwischen 1996 und 2002 .................1 O. Lindner, J. Vogt, A. Kammeier, E. Fricke, J. Holzinger, B. Lamp, D. Baller, D. Horstkotte, W. Burchert Cardiac resynchronisation therapy Kardiale Resynchronisationstherapie ....................................................................................10 S. Höpfner, C. Krolak, S. Kessler, R. Tiling Preoperative imaging of Charcot neuro-arthropathy Präoperative Bildgebung bei diabetisch-neuropathischer Osteoarthropathie.......................15 M. Dietlein, B. Dederichs, C. Kobe, P. Theissen, M. Schmidt, H. Schicha Therapy for non-toxic multinodular goiter Therapiekonzepte der euthyreoten Struma nodosa..............................................................21 M. Schünemann, G. Heidrich, C.O. Sahlmann, U. Siefker, H. Luig, C. Werner, E. Brunner, J. Meller Improvement of tomographic reconstruction in bone SPECT Optimierung der tomographischen Rekonstruktion in der Skelett-SPECT ...........................35 O. Prante, C. Hocke, S. Löber, H. Hübner, P. Gmeiner, T. Kuwert Tissue distribution of radioiodinated FAUC 113 Bioverteilung von Radioiod-markiertem FAUC 113...............................................................41 M. Henze, N. Özdemir-Sahin, P. Hipp, W. Mier, M. Eisenhut, J. Debus, U. Haberkorn Comparison of diagnostic accuracy of 18F-FDG PET, 123I-IMT- and 99mTc-MIBI SPECT Vergleich der diagnostischen Genauigkeit von 18F-FDG-PET, 123I-IMT- und 99mTc-MIBISPECT ...................................................................................................................................49 R. Klett, M. Puille, D. Steiner, R. Bauer Radiation synovectomy of the knee joint Radiosynoviorthese des Kniegelenkes..................................................................................57 M. Gutberlet, S. Mehl, M. Fröhlich, H. Hausmann, M. Plotkin, J. Ruf, T. Denecke, B. Spors, M. Grothoff, R. Hetzer, R. Felix, H. Amthauer Determination of ventricular volumes in coronary artery disease: Comparison of two gated SPECT analysis tools with MRI Bestimmung ventrikulärer Volumina bei koronarer Herzerkrankung: Vergleich zweier Gated-SPECT-Analyseverfahren mit MRT............................................................................63 II http://www.nuklearmedizin-online.de Inhalt – Nuklearmedizin 2006; 45 (1-6) M. Koehli, D. Monbaron, J. O. Prior, M. L. Calcagni, M. Fivaz-Arbane, J. C. Stauffer, R. C. Gaillard, A. Bischof Delaloye, J. Ruiz SPECT myocardial perfusion imaging: Long-term prognostic value in diabetic patients with and without coronary artery disease Myokardperfusion SPECT: Stellenwert in der Langzeit-Prognose diabetischer Patienten mit und ohne koronarer Herzkrankheit..................................................................74 L. Geworski, K. Zöphel, A. Rimpler, I. Barth, M. Lassmann, D. Sandrock, A. Zander, T. Halm, H. Hänscheid, M. Hofmann, Chr. Reiners, D. L. Munz Radiation exposure in 90Y-Zevalin therapy: Results of a prospective multicentre trial Strahlenexposition bei der 90Y-Zevalin-Therapie: Ergebnisse einer prospektiven multizentrischen Studie..........................................................................................................82 W. Römer, A. Nömayr, H. Greess, E. Fiedler, G. Platsch, B. Schuler-Thurner, A. Pfahlberg, T. Hothorn, G. Schuler, J. Hornegger, W. Bautz, T. Kuwert Retrospective interactive rigid fusion of 18F-FDG-PET and CT: Additional diagnostic information in melanoma patients Retrospektive interaktive starre Fusion von 18F-FDG-PET und CT: zusätzliche diagnostische Information bei Patienten mit malignem Melanom.........................................88 H. Vogt, H. Wengenmair, J. Kopp, R. Dorn, I. Otto, J. Sciuk Radioiodine therapy for combined disseminated and nodular thyroid autonomy Radioiodtherapie bei kombinierter Schilddrüsenautonomie................................................101 J. Bucerius, C. Herkel, A. Y. Joe, C. Altehoefer, J. Finke, E. Moser, M. J. Reinhardt F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma 18 F-FDG-PET und konventionelle Bildgebung zur Diagnostik von Morbus Hodgkin und Non-Hodgkin-Lymphomen...................................................................................................105 18 R. Czepczyński, I. Smolarek, D. Rogacka, M. Kaźmierczak, H. Wysocki, J. Sowiński Myocardial perfusion SPECT with dipyridamole stress test in cardiac syndrome X Myokardperfusionsszintigraphie mit dem Dipyridamol-Belastungstest im kardialen Syndrom X ...........................................................................................................................111 B. Schommartz, K. Cupisti, C. Antke, D. Schmidt, W.-T. Knoefel, H.-W. Müller Localisation of parathyroid glands using planar 99mTc-sestamibi scintigraphy Lokalisation von Nebenschilddrüsenadenomen mit planarer 99mTc-SestamibiSzintigraphie ........................................................................................................................115 M. Gotthardt, M. Stübinger, J. Pansegrau, B. Buchwald, J. Goecke, A. Pfestroff, F. H. M. Corstens, T. M. Behr Decrease of 99mTc-uptake in autonomous thyroid tissue in Germany since the 1970s Abfall des 99mTc-Uptakes in autonomem Schilddrüsengewebe in Deutschland seit den 1970er Jahren......................................................................................................................122 M.-J. Martínez, Y. Bercier, M. Schwaiger, S. I. Ziegler PET/CT BiographTM Sensation 16 PET/CT BiographTM Sensation 16 .....................................................................................126 G. Glatting, T. Kull, N. M. Blumstein, D. Bunjes, B. Neumaier, A. K. Buck, S. N. Reske Dosimetry with 188Re-labelled monoclonal anti-CD66 antibodies Dosimetrie mit 188Re-markierten monoklonalen anti-CD66 Antikörpern .............................134 III http://www.nuklearmedizin-online.de Inhalt – Nuklearmedizin 2006; 45 (1-6) P. Männer, B. Tege, E. Fuchs, H. G. Reicherzer, M. Kurz, J. Marienhagen, J. Schönberger, W. Börner, Chr. Eilles Integration of PACS and HIS into the workflow of a nuclear medicine department Integration von PACS und KIS in den Workflow einer nuklearmedizinischen Abteilung....139 M. Schmidt, T. Simon, B. Hero, W. Eschner, M. Dietlein, F. Sudbrock, R. Bongartz, F. Berthold, H. Schicha Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? Gibt es einen Nutzen durch die 131I-MIBG-Therapie bei der Behandlung von Kindern mit Neuroblastom Stadium 4? .............................................................................................145 B. Meller, K. Sommer, J. Gerl, K. von Hof, A. Surowiec, E. Richter, B. Wollenberg, M. Baehre High energy probe for detecting lymph node metastases with 18F-FDG in patients with head and neck cancer Hochenergie-Sonde zur Detektion von Lymphknotenmetastasen mit 18F-FDG bei Patienten mit Kopf-Hals-Tumoren .......................................................................................153 R. Krause, C. Piswanger-Soelkner, R. W. Lipp, F. Daxböck, W. J. Schnedl, S. Hoier, E. C. Reisinger Somatostatin receptor scintigraphy in patients with cat-scratch disease Somatostatinrezeptor-Szintigraphie bei Patienten mit Katzenkratzkrankheit .....................160 M. Beheshti, A. Khorsand, S. Graf, G. Dobrozemsky, S. Oezer, K. Kletter, R. Dudczak, C. Pirich FDG gamma camera PET equipped with one inch crystal and XCT Mit Ein-Zoll-Kristallen ausgerüstete Gammakamera-PET und -XCT..................................163 S. Graf, A. Khorsand, G. Stix, S. Nekolla, A. Becherer, K. Kletter, R. Dudczak, H. Sochor, G. Maurer, G. Porenta Attenuation correction for myocardial perfusion imaging Myokardperfusionsszintigraphie mit Schwächungskorrektur ..............................................171 H. Amthauer, T. Denecke, B. Hildebrandt, R. Rühl, A. Miersch, A. Nicolaou, J. Ruf, M. Plotkin, E. L. Hänninen, C. Stroszczynski, M. Gutberlet, J. Langrehr, H. Riess, J. Ricke Evaluation of patients with liver metastases from colorectal cancer for locally ablativetreatment with laser induced thermotherapy Evaluation von Patienten mit Lebermetastasen kolorektaler Karzinome vor lokalablativer Therapie mittels Laser-induzierter Thermotherapie ......................................177 J. H. Risse, C. Rabe, D. Pauleit, K. Reichmann, C. Menzel, F. Grünwald, H. Strunk, H.-J. Biersack, H. Palmedo Therapy of hepatocellular carcinoma with iodine-131-lipiodol Therapie des hepatozellulären Karzinoms mit Iod-131-Lipiodol .........................................185 A. Lange-Nolde, T. Zajic, M. Slawik, I. Brink, M. Reincke, E. Moser, S. Hoegerle PET with 18F-DOPA in the imaging of parathyroid adenoma in patients with primary hyperparathyroidism PET mit 18F-DOPA zur Darstellung von Nebenschilddrüsenadenomen bei primären Hyperparathyreoidismus......................................................................................................193 G. Henriksen, M. E. Spilker, T. Sprenger, A. I. Hauser, S. Platzer, H. Boecker, T. R. Toelle, M. Schwaiger, H.-J. Wester Gender dependent rate of metabolism of the opioid receptor-PET ligand [18F]fluoroethyl-diprenorphine Geschlechtsspezifische Unterschiede im Metabolismus des opioidergen PET-Liganden [18F]Fluorethyl-diprenorphin .................................................................................................197 IV http://www.nuklearmedizin-online.de Inhalt – Nuklearmedizin 2006; 45 (1-6) J. K. Lee, R. S. Liu, S. Y. Wu, W. S. Huang, M. C. Chou Thallium-201 scan in evaluating thyroid nodules following equivocal fine-needle aspiration cytology Thallium-201-Szintigraphie zur Beurteilung von Schilddrüsenknoten bei unklarer Feinnadelaspirationszytologie .............................................................................................201 M. Gotthardt, C. Rubner, A. Bauhofer, F. Berce, W. J. G. Oyen, J. Goecke, A. Pfestroff, A. Schlieck, F. H. Corstens, M. Béhé, T. M. Behr What is the best pre-therapeutic dosimetry for successful radioiodine therapy of multifocal autonomy? Was ist die beste prätherapeutische Dosimetrie für eine erfolgreiche Radioiodtherapie multifokaler Autonomien? ....................................................................................................206 S. Dunkelmann, H. Künstner, E. Nabavi, U. Eberlein, P. Groth, C. Schümichen Lithium as an adjunct to radioiodine therapy in Graves’ disease for prolonging the intrathyroidal effective half-life of radioiodine Lithium als Zusatz zur Radioiodtherapie bei Morbus Basedow zur Verlängerung der intrathyroidalen effektiven Halbwertszeit von Radioiod.......................................................213 K. P. Schäfers, R. Raupach, T. Beyer Combined 18F-FDG-PET/CT imaging of the head and neck Kombinierte 18F-FDG-PET/CT-Bildgebung im HNO-Bereich..............................................219 M. Voth, R. Klett, P. Lengsfeld, G. Stephan, E. Schmid Biological dosimetry after yttrium-90 citrate colloid radiosynoviorthesis Biologische Dosimetrie nach Radiosynoviorthese mit einem Yttrium-90-Zitratkolloid........223 L. S. Freudenberg, T. Beyer, S. P. Müller, R. Görges, A. Hopfenbach, A. Bockisch Evil radioactivity Radioaktivität ist böse..........................................................................................................229 I. Buchmann, T. Hansen, C. Brochhausen, W. Kneist, K. Oberholzer, T. Junginger, M. Schreckenberger, P. Bartenstein FDG-PET in the initial staging of squamous cell oesophageal carcinoma FDG-PET zum initialen Staging bei Plattenepithelkarzinom des Ösophagus ....................235 N. Döbert, A. F. Kovács, C. Menzel, K. Engels, W. T. Kranert, F. Grünwald FDG uptake after intraarterial chemotherapy in head and neck cancer FDG-Aufnahme nach intraarterieller Chemotherapie bei Kopf-Hals-Tumoren ...................243 S. Graf, M. Nikfardjam, A. Khorsand, S. Ofluoglu, S. Nekolla, R. Dudczak, G. Maurer, K. Kletter, K. Huber, C. Pirich 13 N-ammonia rest/stress PET 13 N-Ammoniak-PET .............................................................................................................248 F. Sudbrock, W. Eschner, M. Schmidt, T. Simon, B. Hero, H. Schicha Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG Dosimetrie bei der Therapie von Neuroblastomen mit 131I-mIBG .......................................254 W. U. Kampen, E. Matis, N. Czech, Z. Soti, S. Gratz, E. Henze Serious complications after radiosynoviorthesis Gravierende Komplikationen nach Radiosynoviorthese .....................................................262 G. Glatting, M. Landmann, A. Wunderlich, T. Kull, F. M. Mottaghy, S. N. Reske Internal radionuclide therapy Therapie mit offenen Radionukliden....................................................................................269 H. Lerch, A. Jigalin Molecular imaging and molecular guided therapy Molekulare Bildgebung und molekular geführte Therapie...................................................273 V http://www.nuklearmedizin-online.de Inhalt – Nuklearmedizin 2006; 45 (1-6) CME-Fortbildung – Education M. Dietlein, B. Dederichs, C. Kobe, P. Theissen, M. Schmidt, H. Schicha Therapy for non-toxic multinodular goiter Therapiekonzepte der euthyreoten Struma nodosa..............................................................21 L. Geworski, K. Zöphel, A. Rimpler, I. Barth, M. Lassmann, D. Sandrock, A. Zander, T. Halm, H. Hänscheid, M. Hofmann, Chr. Reiners, D. L. Munz Radiation exposure in 90Y-Zevalin therapy: Results of a prospective multicentre trial Strahlenexposition bei der 90Y-Zevalin-Therapie: Ergebnisse einer prospektiven multizentrischen Studie..........................................................................................................82 J. Bucerius, C. Herkel, A. Y. Joe, C. Altehoefer, J. Finke, E. Moser, M. J. Reinhardt F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma 18 F-FDG-PET und konventionelle Bildgebung zur Diagnostik von Morbus Hodgkin und Non-Hodgkin-Lymphomen...................................................................................................105 18 M. Schmidt, T. Simon, B. Hero, W. Eschner, M. Dietlein, F. Sudbrock, R. Bongartz, F. Berthold, H. Schicha Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? Gibt es einen Nutzen durch die 131I-MIBG-Therapie bei der Behandlung von Kindern mit Neuroblastom Stadium 4? .............................................................................................145 S. Dunkelmann, H. Künstner, E. Nabavi, U. Eberlein, P. Groth, C. Schümichen Lithium as an adjunct to radioiodine therapy in Graves’ disease for prolonging the intrathyroidal effective half-life of radioiodine Lithium als Zusatz zur Radioiodtherapie bei Morbus Basedow zur Verlängerung der intrathyroidalen effektiven Halbwertszeit von Radioiod.......................................................213 I. Buchmann, T. Hansen, C. Brochhausen, W. Kneist, K. Oberholzer, T. Junginger, M. Schreckenberger, P. Bartenstein FDG-PET in the initial staging of squamous cell oesophageal carcinoma FDG-PET zum initialen Staging bei Plattenepithelkarzinom des Ösophagus ....................235 Der besondere Fall – Special Case Report T. Athanasoulis, J. Koutsikos, K. Korovesis, J. Bokos, C. Zerva Supernumerary parathyroid glands with an unusual ectopic location in recurrent secondary hyperparathyroidism ........................................................................................... N4 A. Hofmann, P. John, M. P. Schaffarich, H. Sinzinger, A. Staudenherz Statins as a new therapeutic approach in dedifferentiated thyroid cancer? ...................... N28 R. Hodek-Wuerz, M. A. Walter, J. Mueller-Brand Puzzling intestinal uptake in 99mTc-DPD bone scintigraphy ............................................... N41 F. G. Fuechsel, S. Weidner, T. Krause Focal pelvic uptake in 18F-FDG PET due to a contraceptive device.................................. N42 F. Büther, K. P. Schäfers, L. Stegger, F. Range, R. Fischbach, T. Wichter, M. Schäfers, O. Schober Artifacts caused by contrast agents and patient movement in cardiac PET-CT................ N53 G. Zettinig, F. Wrba, F. Trautinger, P. Peloschek, A. Luger Necrobiotic panniculitis due to repeated insulin injection................................................... N64 VI http://www.nuklearmedizin-online.de Keywords – Nuklearmedizin 2006; 45 (1-6) Activity leakage ..................... 57 Anti-CD66............................ 134 Attenuation correction . 163, 171 Autonomy ............................ 122 Autoradiography .................... 41 Benign thyroid disorder ....... 122 Biological dosimetry ............ 223 Bone detritus ......................... 15 Bone scintigraphy.................. 35 β-rays .................................... 82 Bremsstrahlung ............... 57, 82 Cancer therapy.................... 185 Cardiac MRI .......................... 63 Cardiac syndrome X............ 111 Cardiac volumetry ................. 63 Cat-scratch disease............. 160 Cervical lymph nodes .......... 243 Chromosome aberration...... 223 Cold thyroid nodule ............. 201 Collective effective dose.......... 1 Colorectal cancer ................ 177 Computed tomography........ 105 Coronary angiography......... 111 Coronary artery disease ............................. 63, 74, 248 Coronary flow reserve ......... 248 Cultural anthropology .......... 229 D4 receptor............................ 41 Dedicated PET .................... 163 Diabetes mellitus ................... 74 Diabetic neuropathic osteoarthropathy................ 15 Diagnostic nuclear medicine.... 1 Diprenorphine...................... 197 Dipyridamole ....................... 111 Dosimetrie .. 101, 134, 206, 213, 254, 269 Dual-phase technique ......... 115 Endocrinology...................... 206 18 F-DOPA ............................ 193 F-FDG............................... 153 FDG-PET............... 88, 235, 243 Filtered backprojection .......... 35 Fine-needle aspiration cytology ......................................... 201 Fluorine-18 .......................... 197 Frequency of procedures ........ 1 18 Gamma camera PET........... 163 Gated SPECT........................ 63 Gender differences.............. 197 Graves' disease................... 213 Head and neck ............ 153, 219 Heart failure..................... 10, 63 Hepatocellular carcinoma.... 185 High energy gamma probe ............................... 153 High risk neuroblastoma...... 145 HIS ...................................... 139 Hodgkin's disease ............... 105 Homocysteine ......................248 123 I-IMT SPECT .....................49 I................................145, 206 Ibritumomab tiuxetan .............82 Image fusion ..........................88 Infection ...............................262 Intraarterial chemotherapy ..................243 Iodine-131-lipiodol ...............185 Iterative reconstruction ..........35 131 Laser induced thermotherapy ..................177 Left bundle branch block........10 Levothyroxine ........................21 Lithium .................................213 Liver metastases..................177 Long term analysis...............185 Low grade astrocytoma .........49 Magnetic resonance imaging ......................15, 105 Malignancy...........................201 Medical anthropology...........229 Melanoma..............................88 Metabolism ..........................197 Metal artifacts ......................219 Metastases ..................235, 243 MIBG-Therapie ....................254 MIBI scintigraphy .................193 Modeling ..............................197 Molecular guided therapy .............................273 Molecular imaging................273 Myocardial ischemia ..............74 Myocardial perfusion imaging ............................171 Myocardial scar......................63 Myocardial viability...............163 Necrosis...............................262 NEMA NU 2-2001 ................126 Neuroblastom ......................254 Noise-equivalent count-rate.........................126 Non-Hodgkin's lymphoma....105 Non-toxic multinodular goiter ..................................21 Nuclear medicine workflow ..139 Oesophageal cancer............235 Oxygen consumption .............10 Primary hyper-parathyreoidism ................................ 115, 193 Prognostic value.................... 74 Radiation............... 82, 223, 229 Radiation synovectomy ......... 57 Radioimmunotherapy .... 82, 134 Radioiodine therapy ..21, 101, 122, 206, 213, 229, Radioligand ........................... 41 Radionuclide therapy .......... 269 Radiosynoviorthesis .... 223, 262 Radiotherapy......................... 49 Recombinant human TSH..... 21 Reconstruction algorithms..... 35 Residence time ........... 134, 269 RIS ...................................... 139 ROC analysis ........................ 49 SAP R/3 .............................. 139 Sestamibi-scintigraphy ........ 115 Skin dose .............................. 82 Somatostatin receptor scintigraphy ..................... 160 Single-photon emission computed tomography, SPECT ............ 35, 74, 111, 171, 254 Spiral computed tomography........................ 88 Squamous cell carcinoma................ 235, 243 Stage 4 neuroblastoma ....... 145 Standardized uptake value................................ 243 Subtraction technique ......... 115 Synovitis.............................. 262 99m Tc-MIBI SPECT ................ 49 Tc-Sestamibi .................. 111 TcTUs ................................. 122 Thallium-201 scan............... 201 Thrombosis ......................... 262 Thyroid ........................ 101, 106 Tomographic data ............... 269 Treatment planning ..... 134, 269 Tumour staging ................... 235 99m Ultrasonography.................. 193 Yttrium-90 ............... 57, 82, 223 Zevalin .................................. 82 PACS...................................139 Patient exposure......................1 Perception ...........................229 Perfusion ...............................10 Phantom study.......................57 Pico-3D electronics..............126 Plummers´ disease ..............122 Polar map analysis ..............171 Portal vein thrombosis .........185 Positron emission tomography, PET10, 15, 88, 105, 126, 153, 171, 177, 193, 197, 219, 248 VII http://www.nuklearmedizin-online.de Schlüsselworte – Nuklearmedizin 2006; 45 (1-6) Abschwächungskorrektur.... 163 Aktivitäsabtransport............... 57 Anti-CD66............................ 134 Autonomie ........................... 122 Autoradiographie ................... 41 Benigne Schilddrüsenerkrankung .. 122 Bildfusion............................... 88 Biologische Dosimetrie........ 223 Bremsstrahlung ............... 57, 82 β-Strahlung............................ 82 Chromosomenaberration..... 223 Computertomographie......... 105 D4-Rezeptor .......................... 41 Diabetes mellitus ................... 74 Diabetisch-neuropatische Osteoarthropathie .............. 15 Diprenorphin........................ 197 Dipyridamol ......................... 111 Dosimetrie .. 101, 134, 206, 213, 254, 269 Endokrinologie..................... 206 Energiedosis........................ 254 Euthyreose ............................ 21 18 F-DOPA ............................ 193 F-FDG....................... 153, 163 18 F-FDG PET......................... 49 FDG-PET....... 88, 177, 235, 243 Feinnadelaspirationszytologie .......................... 201 Fluor-18............................... 197 18 Gammakamera-PET ........... 163 Ganzkörperszintigraphie ..... 254 GatedSPECT......................... 63 Gefilterte Rückprojektion ....... 35 Geschlechtsspezifische Unterschiede.................... 197 Hautdosis .............................. 82 Hepatozelluläres Karzinom.. 185 Herzinsuffizienz ............... 10, 63 HNO .................................... 219 Hochenergiesonde .............. 153 Hochrisiko-Neuroblastom .... 145 Homocystein........................ 248 123 I-IMT SPECT ..................... 49 I ....................................... 206 131 I-MIBG-Therapie.............. 145 Ibritumomab Tiuxetan............ 82 Infektion............................... 262 Intraarterielle Chemotherapie ................ 243 Iod-131-Lipiodol................... 185 Iterative Rekonstruktion......... 35 131 Kalter Schilddrüsenknoten..........201 Kardiale MRT.........................63 Kardiale Volumetrie ...............63 Kardiales Syndrom X ...........111 Katzenkratzkrankheit ...........160 KIS.......................................139 Knochendetritus.....................15 Kollektive effektive Dosis .........1 Kolorektales Karzinom.........177 Kombinierte Schilddrüsenautonomie....101 Kopf-Hals-Tumore ...............153 Koronarangiographie ...........111 Koronare Flussreseve..........248 Koronare Herzerkrankung....63, 74, 248 Kulturanthropologie..............229 Langzeitanalyse...................185 Laser-induzierte Thermotherapie................177 Lebermetastasen .................177 Levothyroxin ..........................21 Linksschenkelblock................10 Lithium .................................213 Magnetresonanztomographie ...............15, 105 Malignität .............................201 Medizinethnologie................229 Melanom ................................88 Metabolismus.......................197 Metallartefakte .....................219 Metastasierung ....................235 MIBG-Therapie ....................254 MIBI-Szintigraphie ...............193 Modeling ..............................197 Molekular geführte Therapie...........................273 Molekulare Bildgebung ........273 Morbus Basedow .................213 Morbus Hodgkin...................105 Myokardiale Vitalität.............163 Myokardischämie...................74 Myokardnarbe........................63 Myokardperfusion ..........74, 171 Nekrose ...............................262 NEMA NU 2-2001 ................126 Neuroblastom ......................254 Neuroblastom Stadium 4 .....145 Niedriggradiges Astrozytom...49 Non-Hodgkin-Lymphom.......105 Phantommessung ................. 57 Pico-3D-Elektronik .............. 126 Plattenepithel karzinom .................. 235, 243 Polar-Map-Analyse.............. 171 Primärer Hyperparathyreoidismus .......... 115, 193 Radioimmuntherapie ..... 82, 134 Radioiodtherapie .. 21, 101, 122, 206, 213, 229 Radioligand ........................... 41 Radionuklidtherapie ............ 269 Radiosynoviorthese .......................... 57, 223, 262 Rauschäquivalente Zählrate 126 Rekombinantes humanes TSH.................... 21 Rekonstruktionsalgorithmus .. 35 RIS ...................................... 139 ROC-Analyse ........................ 49 SAP R/3 .............................. 139 Sauerstoffverbrauch.............. 10 Schilddrüse ......................... 206 Schwächungskorrektur........ 171 Sestamibi-Szintigraphie ...... 115 Skelettszintigraphie ............... 35 SomatostatinrezeptorSzintigraphie.................... 160 SPECT .... 35, 74, 111, 171, 254 Spiral-CT............................... 88 Staging................................ 235 Standardisierter Uptake-Wert .................... 243 Strahlenexposition................. 82 Strahlenschutz .............. 82, 223 Strahlentherapie.................... 49 Strahlung............................. 229 Struma nodosa...................... 21 Subtraktionstechnik............. 115 Synovalitis........................... 262 99m Tc-MIBI........................... 111 Tc-MIBI SPECT ................ 49 TcTUs ................................. 122 Thallium-201-Szintigraphie . 201 Therapieplanung ......... 134, 269 Thrombose.......................... 262 Tomographische Daten....... 269 Tumortherapie..................... 185 99m Ultraschall ........................... 193 Untersuchungshäufigkeiten..... 1 Ösophaguskarzinom............235 Verweildauer ............... 134, 269 2-Phasen-Technik................115 PACS...................................139 Patientenexposition .................1 Perfusion ...............................10 PET... 10, 15, 88, 105, 153, 171, 193, 197, 248 PET/CT........................126, 219 PET-Leistungsdaten ............126 Pfortaderthrombose .............185 Workflow Nuklearmedizin.... 139 Yttrium-90 ............... 57, 82, 223 zervikale Lymphknoten ....... 243 Zevalin .................................. 82 VIII http://www.nuklearmedizin-online.de Autoren – Nuklearmedizin 2006; 45 (1-6) Altehoefer, C. ...................... 105 Amthauer, H. ................. 63, 177 Antke, C............................... 115 Athanasoulis, T..................... N4 Baehre, M............................ 153 Baller, D................................. 10 Bartenstein, P...................... 235 Barth, I................................... 82 Bauer, R. ............................... 57 Bauhofer, A. ........................ 206 Bautz, W................................ 88 Becherer, A. ........................ 171 Béhé, M. .............................. 206 Beheshti, M. ........................ 163 Behr, T.M..................... 122, 206 Berce, F............................... 206 Bercier, Y............................. 126 Berthold, F........................... 145 Beyer, T....................... 219, 229 Biersack, H.-J. ..................... 185 Bischof Delaloye, A. .............. 74 Blumstein, N.M. ................... 134 Bockisch, A.......................... 229 Boecker, H........................... 197 Börner, W. ........................... 139 Bokos, J................................ N4 Bongartz, R. ........................ 145 Brink, I. ................................ 193 Brix, G. .................................... 1 Brochhausen, C................... 235 Brunner, E. ............................ 35 Bucerius, J........................... 105 Buchmann, I. ....................... 235 Buchwald, B. ....................... 122 Buck, A.K............................. 134 Büther, F............................. N53 Bunjes, D............................. 134 Burchert, W. .......................... 10 Calcagni, M.L. ....................... 74 Chou, M.C. .......................... 201 Corstens, F.H.M. ......... 122, 206 Cupisti, K............................. 115 Czech, N.............................. 262 Czepczyński, R.................... 111 Daxböck, F. ......................... 160 Debus, J. ............................... 49 Dederichs, B.......................... 21 Denecke, T. ................... 63, 177 Dietlein, M. .................... 21, 145 Dobrozemsky, G.................. 163 Döbert, N............................. 243 Dorn, R................................ 101 Dudczak, R.......... 163, 171, 248 Dunkelmann, S.................... 213 Eberlein, U........................... 213 Eilles, Chr............................ 139 Eisenhut, M. .......................... 49 Engels, K............................. 243 Eschner, W.................. 145, 254 Felix, R. ................................. 63 Fiedler, E. ..............................88 Finke, J. ...............................105 Fischbach, R....................... N53 Fivaz-Arbane, M. ...................74 Freudenberg, L.S.................229 Fricke, E. ...............................10 Fröhlich, M. ............................63 Fuchs, E. .............................139 Fuechsel, F.G. .................... N42 Gaillard, R.C. .........................74 Gerl, J. .................................153 Geworski, L............................82 Glatting, G....................134, 269 Gmeiner, P.............................41 Goecke, J. ...................122, 206 Görges, R. ...........................229 Gotthardt, M.................122, 206 Graf, S. ................163, 171, 248 Gratz, S. ..............................262 Greess, H...............................88 Groth, P. ..............................213 Grothoff, M.............................63 Grünwald, F. ................185, 243 Gutberlet, M. ..................63, 177 Haberkorn, U. ........................49 Hacker, M. ...............................1 Hänninen, E.L. .....................177 Hänscheid, H. ........................82 Hahn, K....................................1 Halm, T. .................................82 Hansen, T. ...........................235 Hauser, A.I...........................197 Hausmann, H.........................63 Heidrich, G.............................35 Henriksen, G........................197 Henze, E..............................262 Henze, M. ..............................49 Herkel, C..............................105 Hero, B. .......................145, 254 Hetzer, R. ..............................63 Hildebrandt, B. .....................177 Hipp, P...................................49 Hocke, C................................41 Hodek-Wuerz, R. ................ N41 Hoegerle, S..........................193 Höpfner, S..............................15 Hofmann, A......................... N28 Hofmann, M. ..........................82 Hoier, S................................160 Holzinger, J............................10 Hopfenbach, A. ....................229 Hornegger, J. .........................88 Horstkotte, D..........................10 Hothorn, T..............................88 Huang, W.S. ........................201 Huber, K. .............................248 Hübner, H. .............................41 Jigalin, A..............................273 Joe, A.Y. ..............................105 John, P. .............................. N28 Junginger, T.........................235 Kammeier, A. ........................ 10 Kampen, W.U...................... 262 Kaźmierczak, M................... 111 Kessler, S.............................. 15 Khorsand, A. ....... 163, 171, 248 Klett, R. ......................... 57, 223 Kletter, K. ............ 163, 171, 248 Kneist, W............................. 235 Knoefel, W.-T. ..................... 115 Kobe, C. ................................ 21 Koehli, M. .............................. 74 Kopp, J................................ 101 Korovesis, K..........................N4 Koutsikos, J...........................N4 Kovács, A.F......................... 243 Kranert, W.T........................ 243 Krause, R. ........................... 160 Krause, T. ...........................N42 Krolak, C. .............................. 15 Künstner, H. ........................ 213 Kull, T.......................... 134, 269 Kurz, M................................ 139 Kuwert, T......................... 41, 88 Lamp, B. ............................... 10 Landmann, M. ..................... 269 Lange-Nolde, A. .................. 193 Langrehr, J.......................... 177 Lassmann, M......................... 82 Lee, J.K............................... 201 Lengsfeld, P. ....................... 223 Lerch, H. ............................. 273 Lindner, O. ............................ 10 Lipp, R.W. ........................... 160 Liu, R.S. .............................. 201 Löber, S. ............................... 41 Luger, A. .............................N64 Luig, H................................... 35 Männer, P. .......................... 139 Marienhagen, J. .................. 139 Martínez, M.-J. .................... 126 Matis, E. .............................. 262 Maurer, G. ................... 171, 248 Mehl, S.................................. 63 Meller, B.............................. 153 Meller, J. ............................... 35 Menzel, C. ................... 185, 243 Mier, W.................................. 49 Miersch, A. .......................... 177 Monbaron, D. ........................ 74 Moser, E...................... 105, 193 Mottaghy, F.M. .................... 269 Müller, H.-W. ....................... 115 Müller, S.P. ......................... 229 Mueller-Brand, J..................N41 Munz, D.L.............................. 82 Nabavi, E. ........................... 213 Nekolla, S.................... 171, 248 Neumaier, B. ....................... 134 Nicolaou, A.......................... 177 Nikfardjam, M. ..................... 248 Nömayr, A. ............................ 88 Noßke, D................................. 1 IX http://www.nuklearmedizin-online.de Autoren – Nuklearmedizin 2006; 45 (1-6) Oberholzer, K. ..................... 235 Özdemir-Sahin, N.................. 49 Oezer, S. ............................. 163 Ofluoglu, S........................... 248 Otto, I. ................................. 101 Oyen, W.J.G........................ 206 Palmedo, H.......................... 185 Pansegrau, J. ...................... 122 Pauleit, D............................. 185 Peloschek, P. ..................... N64 Pfahlberg, A........................... 88 Pfestroff, A................... 122, 206 Pirich, C....................... 163, 248 Piswanger-Soelkner, C........ 160 Platsch, G.............................. 88 Platzer, S............................. 197 Plotkin, M....................... 63, 177 Porenta, G. .......................... 171 Prante, O............................... 41 Prior, J.O. .............................. 74 Puille, M................................. 57 Rabe, C. .............................. 185 Range, F............................. N53 Raupach, R. ........................ 219 Reicherzer, H.G................... 139 Reichmann, K...................... 185 Reincke, M. ......................... 193 Reiners, Chr. ................... 97, 82 Reinhardt, M.J. .................... 105 Reisinger, E.C. .................... 160 Reske, S.N. ................. 134, 269 Richter, E............................. 153 Ricke, J. .............................. 177 Riess, H............................... 177 Rimpler, A.............................. 82 Risse, J.H............................ 185 Römer, W. ............................. 88 Rogacka, D.......................... 111 Rubner, C............................ 206 Rühl, R. ............................... 177 Ruf, J............................. 63, 177 Ruiz, J. .................................. 74 Sahlmann, C.O...................... 35 Sandrock, D........................... 82 Schaffarich, M.P. ................ N28 Schäfers, K.P. .............219, N53 Schäfers, M. ....................... N53 Schicha, H............. 21, 145, 254 Schlieck, A........................... 206 Schmid, E............................ 223 Schmidt, D........................... 115 Schmidt, M. ........... 21, 145, 254 Schnedl, W.J. ...................... 160 Schnell-Inderst, P. ................... 1 Schober, O. ........................ N53 Schönberger, J. ................... 139 Schommartz, B.................... 115 Schreckenberger, M. ........... 235 Schümichen, C. ................... 213 Schünemann, M. ................... 35 Schuler, G. ............................ 88 Schuler-Thurner, B. ...............88 Schwaiger, M. ..............126, 197 Sciuk, J. ...............................101 Siefker, U...............................35 Simon, T. .....................145, 254 Sinzinger, H. ....................... N28 Slawik, M. ............................193 Smolarek, I...........................111 Sochor, H.............................171 Sommer, K...........................153 Soti, Z. .................................262 Sowiński, J...........................111 Spilker, M.E. ........................197 Spors, B.................................63 Sprenger, T..........................197 Stamm-Meyer, A......................1 Staudenherz, A. .................. N28 Stauffer, J.C...........................74 Stegger, L. .......................... N53 Steiner, D...............................57 Stephan, G...........................223 Stix, G. .................................171 Stroszczynski, C. .................177 Strunk, H..............................185 Stübinger, M. .......................122 Sudbrock, F. ................145, 254 Surowiec, A..........................153 Tege, B. ...............................139 Theissen, P............................21 Tiling, R. ................................15 Toelle, T.R. ..........................197 Trautinger, F. ...................... N64 Vogt, H.................................101 Vogt, J. ..................................10 Von Hof, K. ..........................153 Voth, M. ...............................223 Walter, M.A. ........................ N41 Weidner, S.......................... N42 Wengenmair, H....................101 Werner, C. .............................35 Wester, H.-J.........................197 Wichter, T. .......................... N53 Wollenberg, B. .....................153 Wrba, F............................... N64 Wu, S.Y. ..............................201 Wunderlich, A. .....................269 Wysocki, H...........................111 Zajic, T.................................193 Zander, A...............................82 Zeittinig, G. ......................... N64 Zerva, C................................ N4 Ziegler, S.I. ..........................126 Zöphel, K. ..............................82 X http://www.nuklearmedizin-online.de